Rituximab Dosing for Refractory Uveitis

Medical Necessity Assessment

• The patient has documented failure of multiple conventional immunosuppressive agents, including mycophenolate and methotrexate, which were discontinued due to recurrent infections, cost, and intolerable side effects, respectively 1

Evidence Supporting Increased Dosing Frequency

• Maintenance dosing of rituximab every 6 months is a common protocol, as noted by the Mayo Clinic Proceedings and Praxis Medical Insights 2, 3
• The American College of Rheumatology guidelines suggest that different doses of rituximab, including IV 500 mg every 6 months, IV 1,000 mg every 4 months, and IV 1,000 mg every 6 months, have been used for remission maintenance, with no comparative trials conducted to determine the optimal dose 1, 4

Steroid-Sparing Rationale

• Long-term high-dose corticosteroid therapy poses significant risks, including weight gain, glaucoma, cataract, hypertension, diabetes, adrenal insufficiency, and osteoporosis, as noted by the Mayo Clinic Proceedings 2

Safety Considerations

• Rituximab has demonstrated a favorable safety profile in uveitis treatment, with the most common adverse events being infusion reactions, which can be managed with appropriate premedication 3
• Monitoring recommendations include baseline immunoglobulin levels, hepatitis B and C antibody screening, and latent tuberculosis screening, as well as complete blood count with differential at baseline and at 2-4 month intervals during treatment 3

Treatment Algorithm for Refractory Uveitis

• For inadequate response to standard dosing, increasing rituximab frequency to every 3-4 months may be necessary when the patient experiences disease flares before the next scheduled dose, has failed multiple conventional immunosuppressants, or requires high-dose corticosteroids to maintain disease control 1, 2, 4